阿维巴坦使产NDM-1碳青霉烯耐药肺炎克雷伯菌对先天免疫清除敏感
本研究探讨非β-内酰胺类β-内酰胺酶抑制剂阿维巴坦(AVI)对产NDM-1肺炎克雷伯菌与宿主先天免疫相互作用的影响。体外实验显示AVI与LL-37、中性粒细胞、血小板及活性补体血清产生杀菌协同作用;小鼠肺部感染模型中AVI单药降低肺内细菌载量。提示AVI可增敏NDM-1菌株被先天免疫清除。
要点
- AVI虽不直接抑制NDM酶,但可增敏NDM-1菌株被LL-37等先天免疫因子杀灭。
- AVI与新鲜中性粒细胞、血小板及补体活性血清协同杀菌。
- 小鼠模型中AVI单药降低肺部NDM-1菌载量,提示免疫增敏作用。
核心结论
- AVI通过增敏宿主先天免疫清除机制,使产NDM-1肺炎克雷伯菌对LL-37、中性粒细胞、血小板及活性补体血清的杀菌作用更敏感。
- AVI单药在小鼠肺部感染模型中降低产NDM-1肺炎克雷伯菌的肺内载量。
研究设计与样本
- 体外杀菌实验评估AVI与LL-37、新鲜人中性粒细胞、血小板及血清(补体活性)的相互作用。
- 小鼠肺部攻击模型评估AVI单药对产NDM-1肺炎克雷伯菌肺载量的影响。
主要发现
- AVI暴露与LL-37对人源NDM-1产肺炎克雷伯菌产生显著杀菌协同作用。
- AVI显著增敏NDM-1产菌被新鲜分离的人中性粒细胞、血小板及补体活性血清杀灭。
- 小鼠肺部攻击模型中,AVI单药降低产NDM-1肺炎克雷伯菌的肺载量。
临床怎么用
- 标准药敏试验可能低估AVI对产NDM-1肺炎克雷伯菌的体内效果,需考虑免疫增敏作用。
- AVI与宿主先天免疫协同杀菌的发现值得进一步临床转化研究。
局限性
- 原文未明确报告研究样本量、统计阈值及置信区间等定量数据。
- 结论主要基于体外实验和小鼠模型,人体临床证据尚待进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infections caused by New Delhi metallo-β-lactamase (NDM)-producing strains of multidrug-resistant Klebsiella pneumoniae are a global public health threat lacking reliable therapies. NDM is impervious to all existing β-lactamase inhibitor (BLI) drugs, including the non-β-lactam BLI avibactam (AVI). Though lacking direct activity against NDMs, AVI can interact with penicillin-binding protein 2 in a manner that may influence cell wall dynamics. We found that exposure of NDM-1-producing K. pneumoniae to AVI led to striking bactericidal interactions with human cathelicidin antimicrobial peptide LL-37, a frontline component of host innate immunity. Moreover, AVI markedly sensitized NDM-1-producing K. pneumoniae to killing by freshly isolated human neutrophils, platelets, and serum when complement was active. Finally, AVI monotherapy reduced lung counts of NDM-1-producing K. pneumoniae in a murine pulmonary challenge model. AVI sensitizes NDM-1-producing K. pneumoniae to innate immune clearance in ways that are not appreciated by standard antibiotic testing and that merit further study.
引用
- Ulloa ER, Dillon N, Tsunemoto H, et al. Avibactam Sensitizes Carbapenem-Resistant NDM-1-Producing Klebsiella pneumoniae to Innate Immune Clearance. J Infect Dis. 2019. PMID: 30923801. doi:10.1093/infdis/jiz128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。